Sanofi autoimmune skin candidate rilzabrutinib fails in phase 3
- BySeeking Alpha-
Rilzabrutinib, a candidate from Sanofi to treat emphigus, a rare autoimmune skin condition, missed primary and secondary endpoints in a phase 3 trial.
Rilzabrutinib, a candidate from Sanofi to treat emphigus, a rare autoimmune skin condition, missed primary and secondary endpoints in a phase 3 trial.
Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test.Rilzabrutinib was Principia Biopharma Inc's one of the key candidates that Sanofi...
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks(Biotech Stocks Hitting 52-week Highs Sept. 8)Abbott Laboratories (NYSE:...
France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock...
Sanofi has entered into a definitive agreement with Translate Bio for $38.00 per share in cash, which represents a total equity value of $3.2B a fully diluted basis.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Sell | Neutral |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 1.45 | 1.385 | 1.25 | +0.350 | +31.82% | 30.71M | London | |||
| 19.50 | 28.00 | 15.95 | +4.00 | +25.81% | 3.83M | London | |||
| 388.00 | 365.00 | 325.00 | +59.00 | +17.93% | 39.33K | London | |||
| 0.44 | 0.00 | 0.00 | +0.0650 | +17.33% | 204.32M | London | |||
| 1.12 | 1.12 | 1.12 | +0.17 | +18.42% | 5.67M | London | |||
| 4.71 | 4.50 | 4.46 | -1.03 | -18.73% | 247.16K | London | |||
| 0.0825 | 0.00 | 0.00 | -0.0050 | -5.71% | 1.29B | London | |||
| 170.75 | 172.50 | 167.90 | +3.10 | +1.85% | 7.06M | London | |||
| 395.00 | 426.40 | 391.20 | -15.60 | -3.80% | 4.85M | London | |||
| 224.00 | 226.00 | 222.00 | -4.00 | -1.77% | 24.02K | London | |||
| 153.00 | 153.00 | 150.00 | +3.50 | +2.35% | 2.21M | London | |||
| 800.00 | 808.00 | 781.00 | +18.00 | +2.30% | 975.71K | London | |||
| 1,896.50 | 1,922.00 | 1,882.00 | +8.50 | +0.45% | 381.85K | London | |||
| 34.20 | 35.10 | 33.70 | +1.70 | +5.23% | 410.58K | London | |||
| 138.00 | 138.00 | 138.00 | 0.00 | 0.00% | 24.87K | London |
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.